ArticleScientific reports2025
Syringic acid loaded chitosan nanoparticles mitigate glycation associated oxidative stress and inflammation in hyperglycaemic rat model.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- In silico and in vitro insights into the wound-healing potential of syringic acid: protective and regenerative effects on human fibroblasts.BMC pharmacology & toxicology · 2026Article
- Neuroprotective Potential of Free Radical-Scavenging Nanoparticles in Addressing Inflammation and Obesity.IET nanobiotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Syringic acid (SA), a phenolic compound, is found naturally in several plants, fruits, and vegetables and has numerous therapeutic attributes. The objective of the research was to investigate the possible impact of syringic acid nanoparticles (SANPs) on hyperglycemia, particularly in relation to advanced glycation end products, reactive oxygen species, and inflammation. SANPs were prepared by ionic gelation method and characterized. Rats were divided into 5 groups, normal control, high-fat and high-fructose diet (HFFD), HFFD + metformin (120 mg/kg), HFFD + SA (30 mg/kg) and HFFD + SANPs (15 mg/kg). Rats showed a remarkable decrease in body weight (↓31.61%) and fasting blood glucose levels (↓62.63%) in HFFD + SANPs group. The HbA1c decreased from 5.8 ± 0.05% in HFFD to 4.4 ± 0.12% in HFFD + SA and 4.1 ± 0.16% in HFFD + SANPs treatment groups. The administration of SANPs resulted in a considerable improvement (p < 0.001) in the activity of glyoxalase-1 (Glo1, 0.19 ± 0.003 U/mg protein), glyoxalase-2 (Glo2, 0.14 ± 0.002 U/mg protein) and hexokinase-2 (29.19 ± 2.24 ng/dL). There was a significant decrease (p < 0.001) in malondialdehyde (MDA) levels along with increased glutathione (GSH), superoxide-dismutase (SOD) and catalase activity. The in-silico analysis indicated potential binding affinities with hexokinase 2 (-5.4), IL-6 (-5.7), catalase (-5.8), MDA (-5.4) and GSH (-5.1). Furthermore, these interventions resulted in enhancements in the plasma concentrations of lipid profile components as well as improvements in liver function tests and expression of pro-inflammatory cytokines including IL-6, IL-8 and NF-κB. Utilization of SANPs holds promise as a therapeutic strategy for mitigating hyperglycemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.